What are the latest funding news in the synthetic biology market? (October 2026)
Everything we know about the synthetic biology market, in one place. Get our report whether you build or invest.
Synthetic biology funding in August and September 2026 covered a wide range of applications, from programmable cell therapies and genome engineering to automated biofoundries and engineered microbial production.
The 12 latest qualifying rounds represent at least $791 million in disclosed funding, with several large clinical-stage financings accounting for most of the capital raised.
The deal flow also shows that investors are backing both therapeutic synthetic biology platforms and companies applying engineered organisms to agriculture, proteins, pigments, and other industrial products.
And if you want to better understand this new industry, you can download our pitch covering the synthetic biology market.
Insights
- The 12 latest synthetic biology funding rounds represent at least $791 million, but the capital is highly concentrated, showing that investors are still selective rather than funding the market uniformly.
- Encoded Therapeutics, Basecamp Research, and BrainChild Bio alone raised $531 million, meaning the three largest deals account for roughly two-thirds of the disclosed lower-bound funding total.
- Five clearly therapy-first synthetic biology companies raised $567 million combined, highlighting how programmable cells, genetic medicines, and gene-control technologies continue to attract the market's largest checks.
- The median round in this group is about $35 million, far below the $275 million largest financing, showing how a small number of late-stage biotechnology deals significantly lift headline funding totals.
- Four companies raised at least $90 million each, and those four rounds represent $621 million, reinforcing the concentration of synthetic biology venture capital around advanced therapeutic platforms.
- Seven of the 12 qualifying synthetic biology deals were announced in September, while five came from August, suggesting funding activity remained active through the end of the third quarter.
- Industrial synthetic biology rounds were smaller but more diverse, covering biosynthetic pigments, recombinant functional proteins, engineered microalgae, crop genome engineering, and automated protein discovery infrastructure.
- China's recent synthetic biology funding is particularly visible in engineered production organisms, while the largest U.S. rounds are concentrated around clinical genetic medicine and engineered cell therapies.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
Want to know which startups could overtake the giants next? It's all in our synthetic biology market report.
Summary table of the latest funding deals in the synthetic biology market as of October 2026
We define the synthetic biology market as the set of tools, platforms, and products that rely on engineering biological systems using designed DNA, genetic circuits, or engineered organisms.
We include specialized synbio tools and software, biofoundry and automation platforms, and end-use applications in areas like food, agriculture, health, chemicals, and materials where synthetic biology is a core part of how the product is created or performs.
We exclude conventional biotech and pharmaceuticals, basic GMOs, and traditional fermentation or bio-based products where modern synthetic biology methods are not central to the design or production process.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Link Cell Therapies | 28 September 2026 | $30M | Series A extension | Engineered Cell Therapy & Synthetic Genetic Circuits |
| Basecamp Research | 23 September 2026 | $140M | Series C | Genetic Design Platform & Genetic Medicines |
| Spearhead Bio | 17 September 2026 | $1.62M | Seed | Agricultural Genome Engineering |
| Encoded Therapeutics | 9 September 2026 | $275M | Series F | Precision Genetic Medicine & Gene Regulation |
| BrainChild Bio | 8 September 2026 | $116M | Series A | Engineered CAR-T & Cell Therapy |
| Sensible Biotechnologies | 2 September 2026 | $13.52M | Series A reported | mRNA Biofoundry & Synthetic Biology Manufacturing |
| Typewriter Therapeutics | 2 September 2026 | $56M | Series A | Genome Engineering & Genetic Medicines |
| Adaptyv Biosystems | 26 August 2026 | $40M | Series A | Biofoundry & Protein Engineering |
| Daosheng Bio | 22 August 2026 | ≈$13.9M | Pre-A | Engineered Microbes & Biosynthetic Materials |
| Epicrispr Biotechnologies | 11 August 2026 | $90M | Series C | CRISPR Epigenetic Programming & Genetic Medicines |
| NewPro Bioworks | 4 August 2026 | >≈$1.4M | Pre-A | Engineered Microbes & Functional Proteins |
| Yuanyu Biotechnology / Protoga | 3 August 2026 | ≈$13.9M | Series A+ | Engineered Microalgae & Biological Cell Factories |
All the latest funding deals in the synthetic biology market as of October 2026
Link Cell Therapies raised $30 million in a Series A extension in September 2026.
When was it?
Link Cell Therapies announced the additional financing on 28 September 2026.
Who are they?
Link Cell Therapies develops CAR-T cancer therapies that use engineered genetic logic to help immune cells distinguish tumors from healthy tissue.
Geographical focus?
Link Cell Therapies is based in the United States and is initially developing its therapies for U.S. oncology programs, although the technology has broader global potential.
Why do we include them in the synthetic biology market?
Link Cell Therapies belongs to the synthetic biology market because synthetic genetic circuits directly control how its engineered therapeutic cells recognize and attack cancer.
What is the company stage?
Link Cell Therapies is clinical stage, with LNK001 in Phase 1 and additional logic-gated CAR-T programs moving through preclinical development.
How much did they raise?
Link Cell Therapies raised an additional $30 million, bringing its total Series A financing to $90 million.
What round is it?
Link Cell Therapies described the financing as an extension of its Series A round.
Why did they raise?
Link Cell Therapies raised the capital to support LNK001, move additional logic-gated CAR-T candidates forward, and prepare another oncology program for clinical development.
Not every big name makes it. Our synthetic biology market report looks at who stumbled, why, and what the survivors did differently.
Basecamp Research raised $140 million in a Series C in September 2026.
When was it?
Basecamp Research announced its Series C financing on 23 September 2026.
Who are they?
Basecamp Research combines large biological datasets and AI models to design genetic systems and new therapeutic interventions.
Geographical focus?
Basecamp Research operates from London and Boston while building biological datasets and pharmaceutical partnerships across international markets.
Why do we include them in the synthetic biology market?
Basecamp Research belongs to the synthetic biology market because its platform designs programmable DNA and genetic interventions for therapeutic applications.
What is the company stage?
Basecamp Research is at the growth stage, with established pharmaceutical partnerships and a preclinical pipeline of AI-designed medicines.
How much did they raise?
Basecamp Research raised $140 million in this financing.
What round is it?
Basecamp Research raised a Series C round.
Why did they raise?
Basecamp Research raised the capital to train new EDEN models, expand biological datasets, develop its therapeutic pipeline, and deepen pharmaceutical partnerships.
Spearhead Bio raised $1.62 million in seed financing in September 2026.
When was it?
Spearhead Bio announced the financing on 17 September 2026.
Who are they?
Spearhead Bio develops a genome-engineering platform that inserts, replaces, and rearranges large DNA sequences in commercial crops.
Geographical focus?
Spearhead Bio is based in St. Louis and works with agricultural biotechnology, seed, and crop-development companies that can operate internationally.
Why do we include them in the synthetic biology market?
Spearhead Bio belongs to the synthetic biology market because programmable large-scale DNA engineering is the core technology behind its agricultural trait-development platform.
What is the company stage?
Spearhead Bio is at seed stage, with its TAHITI technology already demonstrated in crops and moving toward broader commercial validation.
How much did they raise?
Spearhead Bio raised $1.62 million.
What round is it?
Spearhead Bio raised a seed round using SAFE instruments.
Why did they raise?
Spearhead Bio raised the funding to develop TAHITI further and validate large-DNA crop engineering with agricultural companies.
Encoded Therapeutics raised $275 million in a Series F financing in September 2026.
When was it?
Encoded Therapeutics announced the financing on 9 September 2026.
Who are they?
Encoded Therapeutics engineers gene-therapy vectors and regulatory DNA so therapeutic genes are activated selectively in specific cell types.
Geographical focus?
Encoded Therapeutics is based in the United States and initially focuses on genetic medicines for severe neurological disorders.
Why do we include them in the synthetic biology market?
Encoded Therapeutics belongs to the synthetic biology market because engineered vectors and designed regulatory genetic elements are fundamental to how its medicines function.
What is the company stage?
Encoded Therapeutics is clinical stage and is advancing its lead Dravet syndrome program toward pivotal development.
How much did they raise?
Encoded Therapeutics raised $275 million.
What round is it?
Encoded Therapeutics raised a Series F financing.
Why did they raise?
Encoded Therapeutics raised the funding for pivotal and expansion studies, commercial-scale manufacturing, and continued development of its precision genetic-medicine pipeline.
Some of the most hyped startups in this space lost most of their value. Find out what went wrong in our synthetic biology market report.
BrainChild Bio raised $116 million in a Series A in September 2026.
When was it?
BrainChild Bio announced the Series A on 8 September 2026.
Who are they?
BrainChild Bio develops engineered CAR-T therapies for brain tumors, including cells designed to recognize multiple tumor targets.
Geographical focus?
BrainChild Bio currently concentrates its clinical development in the United States, including programs involving pediatric neuro-oncology centers.
Why do we include them in the synthetic biology market?
BrainChild Bio belongs to the synthetic biology market because engineered immune cells, multiplex targeting, and programmable cellular functions are central to its therapeutic platform.
What is the company stage?
BrainChild Bio is clinical stage, with BCB-276 progressing through a pivotal Phase 2 program and another multi-target CAR-T candidate in development.
How much did they raise?
BrainChild Bio raised $116 million.
What round is it?
BrainChild Bio raised a Series A round.
Why did they raise?
BrainChild Bio raised the capital to fund the pivotal BCB-276 study and continue development of additional engineered CAR-T programs for brain cancers.
Sensible Biotechnologies disclosed $13.52 million in financing in September 2026.
When was it?
Sensible Biotechnologies' financing was publicly disclosed on 2 September 2026.
Who are they?
Sensible Biotechnologies engineers living cells to manufacture therapeutic mRNA and combines the production platform with AI-guided sequence design.
Geographical focus?
Sensible Biotechnologies operates across the United States, United Kingdom, and Slovakia and can serve pharmaceutical partners internationally.
Why do we include them in the synthetic biology market?
Sensible Biotechnologies belongs to the synthetic biology market because engineered host cells are the core manufacturing system used to produce its designed mRNA molecules.
What is the company stage?
Sensible Biotechnologies is in an early scale-up and partnering stage, with its core technology validated and manufacturing capabilities being expanded.
How much did they raise?
Sensible Biotechnologies disclosed approximately $13.52 million sold in the financing.
What round is it?
Sensible Biotechnologies has been described as raising Series A financing, although the underlying public filing does not assign a conventional round label.
Why did they raise?
Sensible Biotechnologies is using new capital as it scales its engineered-cell mRNA manufacturing and sequence-design platform.
Typewriter Therapeutics raised $56 million in a Series A in September 2026.
When was it?
Typewriter Therapeutics announced the financing on 2 September 2026.
Who are they?
Typewriter Therapeutics develops an RNA-delivered system designed to insert complete therapeutic genes at defined locations in a patient's genome.
Geographical focus?
Typewriter Therapeutics operates from Cambridge, Massachusetts and Tokyo, giving the company a combined U.S. and Japanese development footprint.
Why do we include them in the synthetic biology market?
Typewriter Therapeutics belongs to the synthetic biology market because programmable insertion of designed genes into genomic sites is the foundation of its therapeutic platform.
What is the company stage?
Typewriter Therapeutics is preclinical and emerged from stealth while developing its first in-vivo CAR-T and genetic-medicine candidates.
How much did they raise?
Typewriter Therapeutics raised $56 million.
What round is it?
Typewriter Therapeutics raised a Series A round.
Why did they raise?
Typewriter Therapeutics raised the funding to advance its gene-insertion platform and develop in-vivo CAR-T therapies and medicines for inherited diseases.
Is investor excitement matched by real public interest? Find out in our synthetic biology market report.
Adaptyv Biosystems raised $40 million in a Series A in August 2026.
When was it?
Adaptyv Biosystems' Series A was publicly reported on 26 August 2026.
Who are they?
Adaptyv Biosystems operates an automated protein-engineering foundry that builds and experimentally tests large numbers of digitally designed proteins.
Geographical focus?
Adaptyv Biosystems was founded in Switzerland, serves international customers, and is expanding its operations into London.
Why do we include them in the synthetic biology market?
Adaptyv Biosystems belongs to the synthetic biology market because automated DNA construction and biological testing form a dedicated design-build-test platform for engineered proteins.
What is the company stage?
Adaptyv Biosystems has reached product-market fit and is moving into growth, with more than 100 customers and additional laboratory capacity planned.
How much did they raise?
Adaptyv Biosystems raised $40 million.
What round is it?
Adaptyv Biosystems raised a Series A round.
Why did they raise?
Adaptyv Biosystems raised the capital to expand laboratory capacity, establish a London operation, grow its team, and support more complex protein-engineering workflows.
Daosheng Bio raised nearly $13.9 million in a Pre-A round in August 2026.
When was it?
Daosheng Bio's Pre-A financing was announced on 22 August 2026.
Who are they?
Daosheng Bio engineers microorganisms and metabolic pathways to manufacture pigments such as indigo through biological production instead of conventional chemical processes.
Geographical focus?
Daosheng Bio currently focuses its manufacturing and commercialization in China while addressing textile, cosmetics, food, and materials applications with international potential.
Why do we include them in the synthetic biology market?
Daosheng Bio belongs to the synthetic biology market because genome editing and engineered microbial metabolic pathways are central to how its biosynthetic pigments are produced.
What is the company stage?
Daosheng Bio is at the early commercial and industrial scale-up stage, with large-volume fermentation and commercial production capabilities.
How much did they raise?
Daosheng Bio raised nearly RMB100 million, equivalent to approximately $13.9 million at the time.
What round is it?
Daosheng Bio raised a Pre-A round.
Why did they raise?
Daosheng Bio raised the financing to expand biosynthetic indigo production, strengthen its technology platform, and commercialize additional biologically produced materials.
Epicrispr Biotechnologies raised $90 million in a Series C in August 2026.
When was it?
Epicrispr Biotechnologies announced the Series C on 11 August 2026.
Who are they?
Epicrispr Biotechnologies develops programmable CRISPR-based medicines that switch disease-related genes on or off through targeted epigenetic regulation.
Geographical focus?
Epicrispr Biotechnologies is based in the United States and is initially developing therapies for genetically defined diseases such as FSHD.
Why do we include them in the synthetic biology market?
Epicrispr Biotechnologies belongs to the synthetic biology market because its GEMS platform engineers programmable biological systems that control gene expression inside human cells.
What is the company stage?
Epicrispr Biotechnologies is clinical stage, with lead candidate EPI-321 in Phase 1/2 development and moving toward pivotal studies.
How much did they raise?
Epicrispr Biotechnologies raised $90 million.
What round is it?
Epicrispr Biotechnologies raised a Series C round.
Why did they raise?
Epicrispr Biotechnologies raised the capital to advance EPI-321 toward pivotal development and expand its programmable epigenetic-medicine pipeline.
Where the money goes says a lot about who will win. Our synthetic biology market report breaks it down by region.
NewPro Bioworks raised tens of millions of RMB in a Pre-A round in August 2026.
When was it?
NewPro Bioworks' Pre-A financing was announced on 4 August 2026.
Who are they?
NewPro Bioworks engineers microbial production strains to manufacture scarce functional proteins such as recombinant lactoferrin through precision fermentation.
Geographical focus?
NewPro Bioworks is initially focused on China while preparing manufacturing and commercialization capabilities that can support international food and nutrition markets.
Why do we include them in the synthetic biology market?
NewPro Bioworks belongs to the synthetic biology market because engineered microbial chassis and designed protein-expression systems are central to its functional-protein production platform.
What is the company stage?
NewPro Bioworks is at an early commercial and regulatory scale-up stage, with recombinant lactoferrin progressing toward broader production and market access.
How much did they raise?
NewPro Bioworks disclosed tens of millions of RMB, placing the financing comfortably above approximately $1.4 million, although the exact amount was not published.
What round is it?
NewPro Bioworks raised a Pre-A round.
Why did they raise?
NewPro Bioworks raised the financing to accelerate regulatory work, increase manufacturing capacity, and commercialize lactoferrin and other high-value functional proteins.
Yuanyu Biotechnology raised approximately $13.9 million in a Series A+ in August 2026.
When was it?
Yuanyu Biotechnology's Series A+ financing was announced on 3 August 2026.
Who are they?
Yuanyu Biotechnology, also known as Protoga, develops engineered microalgae as biological production systems for proteins, extracellular vesicles, oils, and functional ingredients.
Geographical focus?
Yuanyu Biotechnology currently focuses on China while developing ingredients and biological manufacturing services that can also address international food, health, and cosmetics markets.
Why do we include them in the synthetic biology market?
Yuanyu Biotechnology belongs to the synthetic biology market because cell engineering and metabolic pathway design are used to turn microalgae into controlled production organisms.
What is the company stage?
Yuanyu Biotechnology is in an early growth and industrialization stage, with synthetic-biology R&D, pilot production, and several microalgae-derived products moving toward scale.
How much did they raise?
Yuanyu Biotechnology raised RMB100 million, equivalent to approximately $13.9 million at the time.
What round is it?
Yuanyu Biotechnology raised a Series A+ round.
Why did they raise?
Yuanyu Biotechnology raised the capital to expand automated manufacturing capacity and commercialize new microalgae-derived proteins, vesicles, and other functional products.
Price is often what holds a market back. See how fast that's changing in our synthetic biology market report.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us